Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
IDXX - IDEXX Laboratories, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$665.00
DETAILS
HIGH:
$710.00
LOW:
$620.00
MEDIAN:
$665.00
CONSENSUS:
$665.00
UPSIDE:
25.64%
Stock News
Baron Focused Growth Fund Q2 2026 Portfolio Update
Baron Focused Growth Fund rebounded in Q2 from a disappointing start to the year, with the Fund gaining 13.26% compared with a gain of 24.02% for the Russell 2500 Growth Index. We remain steadfast in our commitment to long-term investing in competitively advantaged, growth businesses. As of June 30, 2026, the Fund owned 28 investments.
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET). A live audio webcast of the fireside chat will be available through.
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
[url="]IDEXX Laboratories, Inc.[/url] (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Exec
Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
American Capital Management Inc. Acquires Shares of 162,110 IDEXX Laboratories, Inc. $IDXX
American Capital Management Inc. bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 162,110 shares of the company's stock, valued at approximately $85,341,000. IDEXX Laboratories makes
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests
IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to increase testing utilization in veterinary practices.
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.
IDEXX Laboratories: Worth The Premium
IDEXX Laboratories remains a buy, supported by a durable moat, strong recurring revenue, and a long-term international growth runway. Recent Q2 2026 results showed 9% organic revenue growth, EPS guidance raised to $14.69–14.94, and robust expansion of diagnostic offerings. Installed base growth for core machines is moderating in the US but remains early-stage internationally, underpinning multi-decade expansion potential.
Aurora Investment Managers LLC. Makes New Investment in IDEXX Laboratories, Inc. $IDXX
Aurora Investment Managers LLC. bought a new stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,638 shares of the company's stock, valued at approximately $2,442,000. IDEXX Laboratories comprises approximately 1.5%
Here is Why Growth Investors Should Buy Idexx (IDXX) Now
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
IDEXX Laboratories, Inc. $IDXX Shares Sold by Empowered Funds LLC
Empowered Funds LLC cut its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 65.7% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,172 shares of the company's stock after selling 7,985 shares during the quarter. Empowered Funds LLC's holdings
IDEXX Laboratories Q2 Earnings Call Highlights
IDEXX Laboratories (NASDAQ: IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing strong recurring diagnostics revenue, product-cost benefits and continued momentum from new product introductions. Chief Financial
IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Amidst Persistent Visit Headwinds
Revenue: Increased approximately 10% as reported and 9% organically.CAG Diagnostics Recurring Revenue: Grew 10.3% organically, with double-digit gains in both t
Price Targets
Idexx Laboratories price target lowered to $710 from $800 at Barclays
$710.00
(was $595.76)
Glen Santangelo
·
Barclays
Idexx Laboratories price target lowered to $620 from $640 at UBS
$620.00
(was $559.86)
UBS
Idexx Laboratories price target lowered to $640 from $730 at UBS
$640.00
(was $569.17)
Andrea Alfonso
·
UBS
Idexx Laboratories price target lowered to $750 from $775 at Piper Sandler
$750.00
(was $644.61)
Piper Sandler
Idexx Laboratories price target lowered to $800 from $850 at Barclays
$800.00
(was $642.94)
Glen Santangelo
·
Barclays
Idexx Laboratories price target lowered to $730 from $750 at UBS
$730.00
(was $639.60)
Andrea Alfonso
·
UBS
Idexx Laboratories price target lowered to $800 from $830 at BTIG
$800.00
(was $639.60)
BTIG
Idexx Laboratories initiated with an Overweight at Barclays
$850.00
(was $706.65)
Glen Santangelo
·
Barclays
Idexx Laboratories price target raised to $805 from $765 at Morgan Stanley
$805.00
(was $721.04)
Morgan Stanley
Idexx Laboratories price target raised to $750 from $710 at UBS
$750.00
(was $722.94)
UBS
Idexx Laboratories price target raised to $830 from $785 at BTIG
$830.00
(was $722.94)
BTIG
IDEXX Laboratories (IDXX) PT Raised to $830 at Jefferies
$830.00
(was $722.94)
Keith Devas
·
Jefferies
Idexx Laboratories price target raised to $785 from $745 at Leerink
$785.00
(was $722.94)
Leerink Partners
IDEXX Laboratories (IDXX) PT Raised to $775 at Stifel
$775.00
(was $722.94)
Jonathan Block
·
Stifel Nicolaus
Stifel Upgrades IDEXX Laboratories (IDXX) to Buy
$700.00
(was $628.54)
Jonathan Block
·
Stifel Nicolaus
Idexx Laboratories initiated with a Neutral at UBS
$720.00
(was $638.89)
Andrea Alfonso
·
UBS
Idexx Laboratories price target raised to $722 from $626 at Morgan Stanley
$722.00
(was $641.94)
Morgan Stanley
Idexx Laboratories price target raised to $785 from $545 at BTIG
$785.00
(was $641.94)
BTIG
Idexx Laboratories price target raised to $640 from $540 at Stifel
$640.00
(was $682.78)
Stifel Nicolaus
Idexx Laboratories price target lowered to $510 from $520 at Stifel
$510.00
(was $495.73)
Jonathan Block
·
Stifel Nicolaus